Table 1 Baseline characteristics of patients, assessed using FACS analysis

 Age, years

70 (57–80)

67 (47–72)

64 (48–72)

43 (32–56)

 Male, n (%)

15 (31)

14 (54)

1 (25)

5 (29)

 Race, Japanese, n (%)

48 (100)

26 (100)

4 (100)

17 (100)

 MPA/GPA/EGPA, n

20/19/9

–

–

–

 GCA/TAK, n

–

15/11

–

–

 Newly diagnosed/major relapse, n

45/3

24/2

4/0

–

 BVAS

12 (8–18)

3 (3–6)

15 (12–19)

–

 Systemic, n (%)

34 (71)

23 (88)

2 (50)

–

 Skin, n (%)

5 (10)

1 (4)

3 (75)

–

 Mucous membranes/eyes, n (%)

5 (10)

0 (0)

0 (0)

–

 Ear, nose, throat, n (%)

22 (46)

0 (0)

0 (0)

–

 Chest, n (%)

28 (58)

0 (0)

1 (25)

–

 Vascular, n (%)

3 (6)

9 (35)

1 (25)

–

 Renal, n (%)

17 (35)

3 (12)

1 (25)

–

 Nervous system, n (%)

20 (42)

0 (0)

3 (75)

–

 ESR, mm/h

87 (40–121)

109 (59–122)

71 (33–112)

–

 White blood cells, 10³ cells/μL

9.5 (7.0–13)

9.5 (7.0–14)

7.7 (6.6–9.1)

–

 Neutrophils, 10³ cells/μL

6.2 (4.4–8.4)

5.4 (4.6–7.0)

6.1 (2.6–8.4)

–

 Lymphocytes, 10³ cells/μL

1.5 (1.0–1.8)

1.4 (1.1–1.8)

1.1 (0.8–1.6)

–

 Monocytes, cells/μL

414 (308–623)

460 (343–565)

444 (235–737)

–

 Eosinophils, cells/μL

223 (116–814)

119 (67–192)

109 (7–755)

–

 Haemoglobin, g/dL

11 (9.6–13)

11 (10–12)

12 (11–13)

–

 Platelets, 10⁴ cells/μL

34 (25–41)

34 (29–42)

28 (18–36)

–

 CRP, mg/dL

3.9 (0.7–8)

4.8 (2.4–6.5)

0.8 (0.3–5.2)

–

 IgG, mg/dL

1648 (1120 − 1905)

1437 (1140–1690)

1325 (1124–2223)

–

 MPO-ANCA-/PR3-ANCA-positive/ANCA-negative, n

34/8/6

1/0/25

0/0/4

–

 MPO-ANCA titre, U/mL

41 (13–171), n = 34

28, n = 1

–

–

 PR3-ANCA titre, U/mL

14 (10–39), n = 8

–

–

–

 Rheumatoid factor positive, n (%)

37 (79)

2 (8)

1 (25)

–

 Rheumatoid factor, IU/mL

65 (32–141)

29 (16–42)

41, n = 1

–